Across TCGA pan-cancer cohorts, RPS23 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RPS23 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher RPS23 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RPS23 expression acts as an unfavorable survival marker.

CESC and LUAD are the cancer types where RPS23 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	All	0.068	0.875	<.001	36	view →
LUAD	OS	Median	All	0.158	0.835	<.001	34	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: RPS23 tumor-vs-normal RNA expression · all RPS23 data types